Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$6.5B

Dec1Thu

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation is a biotechnology company focused on developing innovative cell therapies for cancer and other serious diseases. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as demand for advanced medical treatments continues to grow.

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In the last quarter, Legend Biotech reported an EPS of -$0.16, which was better than the expected -$0.29, marking a 44.44% surprise. However, the stock saw a slight decline of 0.62% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for its lead product candidates.
Commitment to improving operational efficiency.
Plans to expand partnerships for research and development.

Expectations

Wall Street Expectations

Overall, expectations for Legend Biotech's upcoming earnings are mixed, with no analyst estimates available. Investors are keen to see if the company can continue its trend of beating EPS expectations.

Bull Case

If Legend Biotech can report a smaller loss or even a profit, it would signal strong operational improvements and potentially lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of operational struggles, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for this quarter?

The EPS figure will be crucial in determining whether the company can maintain its trend of beating expectations and improve investor confidence.

What updates will be provided on clinical trials?

Investors will be closely watching for any news on the progress of clinical trials, as this could impact future revenue and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Legend Biotech's ability to improve its EPS significantly this quarter, given its recent operational changes.

Supporting Evidence

The company has a history of beating EPS estimates 67% of the time, indicating potential for positive surprises.

Recent operational improvements have not been fully factored into market expectations.

Key Risk

If the EPS loss comes in below $0.10, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Legend Biotech can show signs of operational improvement and progress in its clinical trials.

Bull Confirmed If

An EPS loss of less than $0.10 would confirm the bull case, indicating improved operational efficiency.

Bear Confirmed If

An EPS loss greater than $0.30 would confirm the bear case, suggesting ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing a 5% move in either direction, suggesting that investors expect some volatility around the earnings report.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests a potential stock increase of around 1.71%, confirming positive operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await more clarity from management.

Miss

Should the company miss expectations, history suggests a potential decline of around 6.91%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on the progress of clinical trials.
2Management's commentary on cost management strategies.
3Insights into potential partnerships or collaborations.
4Details on market demand for their therapies.
5Future guidance on revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing clinical trials for its lead product candidates.
Commitment to improving operational efficiency.
Plans to expand partnerships for research and development.

Expectations

Wall Street Expectations

Bull Case

If Legend Biotech can report a smaller loss or even a profit, it would signal strong operational improvements and potentially lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of operational struggles, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for this quarter?

The EPS figure will be crucial in determining whether the company can maintain its trend of beating expectations and improve investor confidence.

What updates will be provided on clinical trials?

Investors will be closely watching for any news on the progress of clinical trials, as this could impact future revenue and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Legend Biotech's ability to improve its EPS significantly this quarter, given its recent operational changes.

Supporting Evidence

The company has a history of beating EPS estimates 67% of the time, indicating potential for positive surprises.

Recent operational improvements have not been fully factored into market expectations.

Key Risk

If the EPS loss comes in below $0.10, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Legend Biotech can show signs of operational improvement and progress in its clinical trials.

Bull Confirmed If

An EPS loss of less than $0.10 would confirm the bull case, indicating improved operational efficiency.

Bear Confirmed If

An EPS loss greater than $0.30 would confirm the bear case, suggesting ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing a 5% move in either direction, suggesting that investors expect some volatility around the earnings report.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests a potential stock increase of around 1.71%, confirming positive operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await more clarity from management.

Miss

Should the company miss expectations, history suggests a potential decline of around 6.91%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific updates on the progress of clinical trials.
2Management's commentary on cost management strategies.
3Insights into potential partnerships or collaborations.
4Details on market demand for their therapies.
5Future guidance on revenue expectations.